Vice President, Operations
Bryan Jones is Vice President of Operations of Scintilla Pharmaceuticals. He was Vice President, Operations of Sorrento Therapeutics from 2013 to 2016 and President/CSO of its subsidiary, ARK Animal Health, from 2014 to 2016. He has led development of resiniferatoxin for treatment of pain associated with inflammation. He has written an ANDA in canines for bone pain associated with cancer and has led the team that has converted an investigator-sponsored IND by the NIH to a corporate IND. He was Chief Operating Officer of two startup companies: Sherrington and Mt. Cook, as well as Senior Director of Business Development at Amylin, and Vice President of Business Development at Kemia. Earlier in his career, he worked in research on products such as Cilais® with ICOS and Orencia® with Bristol-Myers Squibb. Dr. Jones holds a Ph.D. in genetics, which he obtained at the University of Washington.